Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma.

Autor:	Bannaga AS; Department of Gastroenterology and Hepatology, University Hospital, Coventry UK; Warwick Medical School, University of Warwick, Coventry, UK. Electronic address: ayman.bannaga@warwick.ac.uk., Alvarez R; Department of Biomedical Sciences, Cedars-Sinai, Los Angeles CA, USA., Zhou L; Department of Biomedical Sciences, Cedars-Sinai, Los Angeles CA, USA., Petchey M; Department of Pathology, University Hospital, Coventry UK., Noufaily A; Warwick Medical School, University of Warwick, Coventry, UK., Hitchins MP; Department of Biomedical Sciences, Cedars-Sinai, Los Angeles CA, USA., Arasaradnam RP; Department of Gastroenterology and Hepatology, University Hospital, Coventry UK; Warwick Medical School, University of Warwick, Coventry, UK; Faculty of Health & Life Sciences, Coventry University, Coventry, UK; School of Biological Sciences, University of Leicester, Leicester, UK.
Jazyk:	angličtina
Zdroj:	HPB : the official journal of the International Hepato Pancreato Biliary Association [HPB (Oxford)] 2021 Oct; Vol. 23 (10), pp. 1595-1606. Date of Electronic Publication: 2021 Apr 20.
DOI:	10.1016/j.hpb.2021.03.015
Abstrakt:	Background: Methylated septin 9 (mSEPT9) has a role in hepatocarcinogenesis. We evaluated mSEPT9 performance in patients with hepatocellular carcinoma (HCC) and those at risk of HCC METHODS: Using Epi-proColon® V2.0 assay adapted for 1 mL plasma, we investigated mSEPT9 sensitivity, specificity, associations with influential covariates and relation to death. Results: Of 141 participants included, 136 had liver disease, 38 with HCC (mean-age 71 years) and 103 without HCC (mean-age 56.8 years), with further five without liver disease. 41 patients died (23 HCC) by the end of the study follow-up period. In HCC, mSEPT9 sensitivity and specificity were 89.47% (CI:75.20%-97.06%) and 81.55% (CI:72.70%-88.51%), whilst alpha fetoprotein (AFP) sensitivity and specificity were 50% (CI:33.38%-66.62%) and 97.09% (CI:91.72%-99.40%), respectively. Age-adjusted logistic regression showed mSEPT9 was associated with age, body mass index, HCC, liver cirrhosis, AFP, platelets, neutrophil-to-lymphocyte-ratio, albumin-bilirubin grade and fibrosis-4 index (p < 0.05). Odds for HCC patients to have positive mSEPT9 were 27.4 times more than those without HCC. Time-to-death was associated with mSEPT9 positivity (p < 0.05). Kaplan-Meier curves showed higher HCC survival with mSEPT9 compared to AFP. Conclusions: The mSEPT9 offers potential diagnostic and prognostic biomarker for HCC. After adjusting for age, mSEPT9 remained associated with liver function, liver fibrosis and inflammatory surrogate markers. (Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu